Get all premium features to the best stock analysis tool

Doximity (DOCS) reached $23.69 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.

Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report examining how physicians are adopting artificial intelligence (AI) in clinical practice. The findings show that AI adoption and interest are widespread: 94% of physicians reported they are currently using AI or interested in doing so. At the same time, physicians remain cautious, with 71% citing accuracy and reliability as their top concern. “AI h.

Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.

Doximity stock has fallen during the software stock bust in 2026. The business is doing well, is highly profitable, and has a lock on the doctor social media market in the United States.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Doximity remains a Hold as growth visibility weakens and NRR declines to 112%, raising concerns over future expansion. Engagement and profitability are robust, with workflow tools reaching 720,000 unique prescribers and GAAP gross margin near 90%. DOCS boasts a strong balance sheet, $735 million in cash, no debt, and ongoing share repurchases, supporting downside protection.